Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population

Environmental Health and Preventive Medicine

Volumn 18, Issue 2, 2013, Pages 136-142

  Cui, Xiaoyi ^a   Lu, Xi ^a   Hiura, Mizue ^a   Omori, Hisamitsu ^a   Miyazaki, Wataru ^a   Katoh, Takahiko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Genetic susceptibility; N acetyltransferase; Polymorphism; UDP glucuronosyltransferase B7

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1A2; GLUCURONOSYLTRANSFERASE 2B7; SULFOTRANSFERASE 1A1;

ADULT; ARTICLE; ARYLAMINE ACETYLTRANSFERASE GEENE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; CYTOCHROME P450 1A2 GENE; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; GLUCURONOSYLTRANSFERASE 2B7 GENE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SULFOTRANSFERASE 1A1 GENE;

NICOTIANA TABACUM;

EID: 84878517121     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-012-0302-x     Document Type: Article

References (32)

1. International Agency for Research on Cancer (IARC). Reversal of risk after quitting smoking. Lyon: IARC handbook of cancer prevention. 2007.
2. Vineis P, Caporaso N. Tobacco and cancer, epidemiology and the laboratory. Environ Health Perspect. 1995;103:156-60.
3. Talaska G, Al-Jubur AZ, Kadulbar FF. Smoking-related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosine-8-yl)-4-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci USA. 1991;88:5350-4.
4. Tania C, Grace K, Le M, Avima MR, Paul AS. The genetic and environmental factors involved in benzidine metabolism and bladder carcinogenesis in exposed workers. Front Biosci. 2006;11:2889-902.
5. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat Res. 2002;506(507):21-8.
6. Pavanello S, Simioli P, Lupi S, Gregorio P, Clonfero E. Exposure levels and cytochrome P450 1A2 activity, but not Nacetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomarkers Prev. 2002;11:998-1003.
7. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999;125:803-8.
8. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Osada Y, et al. Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol. 2004;130:99-106.
9. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, et al. CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci. 1994;9:482-9.
10. Hein DW, Doll MA, Gray K, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxy-2-acetylaminofluorene by NAT1 and NAT2 in colon cytosols of Syrian hamster congenic at the NAT2 locus. Cancer Res. 1993;53:509-14.
11. Srivastava DS, Mittal RD. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol. 2005;5:12.
12. Ozawa S, Katoh T, Inatomi H, Imai H, Kuroda Y, Ichiba M, et al. Association of genotypes of carcinogen-activating- enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer. 2002;102:418-21.
13. Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact. 2000;129:141-70.
14. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun. 1997;239:298-304.
15. Ozawa S, Tang YM, Yamazoe Y, Kato R, Lang NP, Kadlubar FF. Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact. 1998;109:237-48.
16. Ozawa S, Shimizu M, Katoh T, Miyajima A, Ohno Y, Matsumoto Y, et al. Sulfating-activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 ((213)Arg) and ST1A3*2 ((213)His), both of which exist in Japanese as well as Caucasians. J Biochem. 1999;126:271-7.
17. Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett. 2003;202:61-9.
18. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003;13:517-23.
19. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos. 1998;26:73-7.
20. Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, et al. Single nucleotide poly-morphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos. 2004;32:1048-54.
21. Golka K, Prior V, Blaszkewicz M, Bolt HM. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett. 2002;128:229-41.
22. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase(NAT2) Reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993;14:1689-92.
23. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis. 1998;19:1803-7.
24. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366:649-59.
25. Tsukino H, Nakao H, Kuroda Y, Imai H, Inatomi H, Osada Y, et al. Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking. Eur J Cancer Prev. 2004;13:509-14.
26. Lampe JW, King IB, Li S, Grate MT, Barale KV, Chen C, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000;21:1157-62.
27. Tao L, Xiang YB, Chan KK, Wang R, Gao YT, Yu MC, et al. Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. Int J Cancer. 2012;130:1174-83.
28. Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, et al. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomark Prev. 1999;8:159-66.
29. Zenser TV, Lakshmi VM, Davis BB. N-glucuronidation of benzidine and its metabolites role in bladder cancer. Drug Metab Dispos. 1998;26:856-9.
30. Burchell B, Soars M, Monaghan G, Cassid A, Smith D, Ethell B. Drug-mediated toxicity cased by genetic deficiency of UDP- glucuronosyltransferases. Toxicol Lett. 2000;112-113:333-40.
31. Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog. 2011;10:1002.
32. Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, et al. An association of UDP-glucuronosyltransferase 2B7 C802T(His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci. 2005;85:502-6.